BioArctic

183.4

SEK

+0.82 %

Less than 1K followers

BIOA B

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

+0.82%

-6.43%

-25.02%

-8.07%

-5.02%

-24.4%

+143.72%

+138.65%

+532.41%

BioArctic is a research company. The greatest business focus is found in the research and development of treatments and antibodies for diseases that affect the nervous system. Examples of various diseases mainly include Alzheimer's and Parkinson's. A large part of the research is carried out in collaboration with researchers at universities and hospitals. The company was founded in 2003 and is headquartered in Stockholm, Sweden.

Market cap

16.24B SEK

Turnover

67.37M SEK

Revenue

257.35M

EBIT %

-88.79 %

P/E

-

Dividend yield-%

-

Financial calendar

28.8

2025

Interim report Q2'25

13.11

2025

Interim report Q3'25

18.2

2026

Annual report '25

All

Webcasts

Press releases

ShowingAll content types

Press release13 hours ago

BioArctic's Capital Markets Day 2025 - entering a new era of growth

BioArctic, Capital Markets Day, 2025

Webcast13 hours ago

BioArctic, Capital Markets Day, 2025

Regulatory press release5/30/2025, 4:30 PM

Number of shares and votes in BioArctic AB (publ) as of May 30, 2025

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release5/22/2025, 4:18 PM

Bulletin from the Annual General Meeting in BioArctic AB (publ)

Regulatory press release5/22/2025, 1:15 PM

BioArctic receives positive opinion for Orphan Medicinal Product Designation in the EU for exidavnemab in Multiple System Atrophy

BioArctic, Audiocast with teleconference, Q1'25

Webcast5/21/2025, 7:30 AM

BioArctic, Audiocast with teleconference, Q1'25

Regulatory press release5/21/2025, 6:00 AM

BioArctic: Interim Report for the period January - March 2025

Regulatory press release5/15/2025, 4:00 AM

BioArctic: Eisai projects Leqembi® revenue to total JPY 76.5 billion for fiscal year 2025 (April 2025 - March 2026)

Press release5/13/2025, 6:30 AM

Invitation to presentation of BioArctic's first quarter report for January - March 2025 on May 21 at 9.30 a.m. CET

Press release5/8/2025, 11:30 AM

BioArctic: Exidavnemab phase 2a study expanded to include MSA patients

Regulatory press release5/1/2025, 10:45 AM

BioArctic: Sales of Leqembi[®] totaled 14.7 billion yen in the first quarter 2025

Press release4/30/2025, 7:30 AM

BioArctic: MHRA to evaluate monthly intravenous maintenance dosing of Leqembi[®] for the treatment of early Alzheimer's disease in the UK

Press release4/23/2025, 11:00 AM

BioArctic receives European substance patent for exidavnemab

Regulatory press release4/22/2025, 6:00 PM

BioArctic publishes the Annual Report and Sustainability Report for 2024

Regulatory press release4/22/2025, 6:00 PM

Notice of Annual General Meeting 2025 in BioArctic AB (publ)

Regulatory press release4/15/2025, 11:10 PM

BioArctic: EU approves Leqembi® (lecanemab) for treatment of early Alzheimer's disease (Extended information)

Regulatory press release4/15/2025, 3:25 PM

BioArctic: EU approves Leqembi® (lecanemab) for treatment of early Alzheimer's disease

Regulatory press release4/14/2025, 11:00 AM

BioArctic: The European Commission to make final decision on EU Marketing Authorisation for lecanemab

Regulatory press release4/7/2025, 10:00 AM

BioArctic: Exidavnemab and lecanemab data presented at the 2025 AD/PD™ congress

Regulatory press release4/1/2025, 10:00 AM

BioArctic: The European Commission refers lecanemab decision to Appeal Committee

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.